Monopar Therapeutics (NASDAQ:MNPR) Director Sells $455,585.10 in Stock

Monopar Therapeutics Inc. (NASDAQ:MNPR) Director Kim Tsuchimoto sold 4,090 shares of the stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $111.39, for a total value of $455,585.10. Following the completion of the transaction, the director owned 7,396 shares in the company, valued at approximately $823,840.44. The trade was a 35.61% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Monopar Therapeutics Trading Up 0.2%

MNPR stock traded up $0.22 during trading on Thursday, hitting $113.94. 142,825 shares of the company’s stock were exchanged, compared to its average volume of 220,179. The business has a 50-day moving average price of $104.63 and a two-hundred day moving average price of $74.34. The stock has a market capitalization of $764.77 million, a price-to-earnings ratio of -52.51 and a beta of 1.47. Monopar Therapeutics Inc. has a 52-week low of $32.77 and a 52-week high of $124.82.

Monopar Therapeutics (NASDAQ:MNPR) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.62) EPS for the quarter, beating the consensus estimate of ($0.64) by $0.02. On average, equities research analysts anticipate that Monopar Therapeutics Inc. will post -2.94 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Goldman Sachs Group Inc. acquired a new stake in shares of Monopar Therapeutics during the first quarter worth $673,000. Jane Street Group LLC acquired a new position in Monopar Therapeutics in the 1st quarter valued at $377,000. Geode Capital Management LLC raised its position in Monopar Therapeutics by 99.7% during the 2nd quarter. Geode Capital Management LLC now owns 96,919 shares of the company’s stock worth $3,468,000 after buying an additional 48,379 shares during the last quarter. JPMorgan Chase & Co. raised its position in Monopar Therapeutics by 1,821.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock worth $69,000 after buying an additional 1,821 shares during the last quarter. Finally, Rhumbline Advisers purchased a new position in Monopar Therapeutics during the 2nd quarter worth $209,000. Institutional investors and hedge funds own 1.83% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently commented on MNPR shares. Barclays reiterated an “overweight” rating and set a $128.00 price target (up from $125.00) on shares of Monopar Therapeutics in a research note on Thursday, August 13th. BTIG Research raised their price objective on Monopar Therapeutics from $117.00 to $133.00 and gave the stock a “buy” rating in a report on Wednesday, August 12th. Morgan Stanley reiterated an “overweight” rating and set a $130.00 target price on shares of Monopar Therapeutics in a research report on Monday, August 17th. Wall Street Zen downgraded Monopar Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, August 16th. Finally, UBS Group set a $125.00 target price on Monopar Therapeutics in a research report on Thursday, July 23rd. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Monopar Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $118.67.

Monopar Therapeutics Company Profile

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.